A Quick Look at Today's Ratings for Denali Therapeutics(DNLI.US), With a Forecast Between $27 to $90
On Sep 04, major Wall Street analysts update their ratings for $Denali Therapeutics(DNLI.US)$, with price targets ranging from $27 to $90.Goldman Sachs analyst Salveen Richter maintains with a buy
Denali Therapeutics Is Maintained at Buy by B of A Securities
Denali Therapeutics Price Target Raised to $29.00/Share From $25.00 by B of A Securities
Wedbush Adjusts Price Target on Denali Therapeutics to $27 From $26, Maintains Outperform Rating
Denali Therapeutics' DNL310 Shows Promise for Early Approval and Market Success
Express News | Denali Therapeutics Inc - Plan to Submit Biologics License Application (Bla) Early in 2025 Under Accelerated Approval Pathway